I60
Conditions
Interventions
Group 1: At the beginning of surgery/endovascular treatment, all patients routinely receive i.v. nimodipin 1.0 mg/h over 6 hours, following 2.0 mg/h for 7 days dependent on the mean arterial blood pre
Sponsors
Klinik für Neurochirurgie, Universitätsklinikum Augsburg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: a) Minimum age of 18 years, both genders. b) Written informed consent of the participant or his/her legal guardian c) Patients with imaging-proof of aneurysmal subarachnoid hemorrhage d) Endovascular or microsurgical treatment within 12 hours after onset of SAH plus implantation of an external CSF drainage.
Exclusion criteria
Exclusion criteria: a) pregnancy and breastfeeding b) bodyweight <50kg c) decompensated kidney disease (GFR <15ml/min) d) acute coronary syndrome within the past 6 months e) expected survival <48 hours
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma and cerebrospinal fluid concentrations of calcium and magnesium on day 3 after bleeding | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. QoL (SAHOT questionaire) and overall survival after 3 and 6 months of follow-up, 2. Cerebral vasospasm and 3. Delayed ischemic deficite between day 3 and 14 after bleeding | — |
Countries
Germany
Contacts
Public ContactBjörn Sommer
Klinik für Neurochirurgie, Universitätsklinikum Augsburg
Outcome results
None listed